RenovaroRENB
About: Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Employees: 25
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
371% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 7
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
159% more capital invested
Capital invested by funds: $7.13M [Q3] → $18.5M (+$11.4M) [Q4]
16% more funds holding
Funds holding: 50 [Q3] → 58 (+8) [Q4]
3.93% more ownership
Funds ownership: 10.01% [Q3] → 13.94% (+3.93%) [Q4]
15% less call options, than puts
Call options by funds: $35K | Put options by funds: $41K
Research analyst outlook
We haven’t received any recent analyst ratings for RENB.
Financial journalist opinion
Based on 3 articles about RENB published over the past 30 days









